Literature DB >> 3536980

Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus.

G M Reaven, Y D Chen, A Golay, A L Swislocki, J B Jaspan.   

Abstract

Plasma glucose, insulin, FFA, glucagon, and GH concentrations were measured over an 8-h period in normal subjects and patients with noninsulin-dependent diabetes mellitus (NIDDM). Meals were consumed at 0800 h (20% of daily calories) and noon (40% of daily calories), and measurements were made hourly from 0800-1600 h. Day-long plasma glucose, insulin, and FFA concentrations were higher than normal (by two-way analysis of variance) in patients with NIDDM, whether obese or nonobese. In addition, day-long plasma glucagon concentrations were also higher than normal (by two-way analysis of variance) in both nonobese and obese patients with NIDDM. Furthermore, direct relationships were found between the total plasma glucagon response from 0800-1600 h and total plasma glucose (r = 0.57; P less than 0.001) and FFA (r = 0.30; P less than 0.06) responses. In contrast, plasma GH levels were not increased in patients with NIDDM. These data demonstrate that ambient plasma concentrations of both glucose and FFA are higher in patients with NIDDM, despite the fact that coexisting plasma insulin levels are equal to or higher than normal. The higher day-long plasma glucagon levels in patients with NIDDM may contribute to their higher plasma glucose and FFA concentrations.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3536980     DOI: 10.1210/jcem-64-1-106

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  98 in total

Review 1.  Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.

Authors:  Philip E Cryer
Journal:  Endocrinology       Date:  2011-12-13       Impact factor: 4.736

2.  Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.

Authors:  Kyle W Sloop; Julia Xiao-Chun Cao; Angela M Siesky; Hong Yan Zhang; Diane M Bodenmiller; Amy L Cox; Steven J Jacobs; Julie S Moyers; Rebecca A Owens; Aaron D Showalter; Martin B Brenner; Achim Raap; Jesper Gromada; Brian R Berridge; David K B Monteith; Niels Porksen; Robert A McKay; Brett P Monia; Sanjay Bhanot; Lynnetta M Watts; M Dodson Michael
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 3.  Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes.

Authors:  Xiao C Li; Jia L Zhuo
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

4.  Dual mode of glucagon receptor internalization: role of PKCα, GRKs and β-arrestins.

Authors:  Lada Krilov; Amy Nguyen; Teruo Miyazaki; Cecilia G Unson; Russell Williams; Norman H Lee; Susan Ceryak; Bernard Bouscarel
Journal:  Exp Cell Res       Date:  2011-10-06       Impact factor: 3.905

5.  Glucagon receptor-mediated extracellular signal-regulated kinase 1/2 phosphorylation in rat mesangial cells: role of protein kinase A and phospholipase C.

Authors:  Xiao C Li; Oscar A Carretero; Yuan Shao; Jia L Zhuo
Journal:  Hypertension       Date:  2006-01-03       Impact factor: 10.190

6.  Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.

Authors:  F K Knop; T Vilsbøll; S Madsbad; J J Holst; T Krarup
Journal:  Diabetologia       Date:  2007-01-16       Impact factor: 10.122

7.  Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition.

Authors:  Haruka Okamoto; Katie Cavino; Erqian Na; Elizabeth Krumm; Steven Kim; Panayiotis E Stevis; Joyce Harp; Andrew J Murphy; George D Yancopoulos; Jesper Gromada
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-31       Impact factor: 11.205

8.  Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet.

Authors:  M Sörhede Winzell; C L Brand; N Wierup; U G Sidelmann; F Sundler; E Nishimura; B Ahrén
Journal:  Diabetologia       Date:  2007-05-04       Impact factor: 10.122

9.  Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with Type 2 diabetes.

Authors:  M Shimodaira; Y Muroya; N Kumagai; K Tsuzawa; K Honda
Journal:  J Endocrinol Invest       Date:  2013-04-12       Impact factor: 4.256

10.  Weight loss therapy improves pancreatic endocrine function in obese older adults.

Authors:  Dennis T Villareal; Marian R Banks; Bruce W Patterson; Kenneth S Polonsky; Samuel Klein
Journal:  Obesity (Silver Spring)       Date:  2008-04-03       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.